Skip to main content

Nanogen s Q2 Revenues Almost Triple, Loss Narrows

NEW YORK, Aug. 3 (GenomeWeb News) - Nanogen yesterday reported a jump in revenues and narrowed losses for the second quarter of 2005.


The company's revenues for the quarter almost tripled, to $3.1 million from $1.1 million during the same period last year. Product revenues were $1.1 million of the total, up from $500,000 during the year-ago period. "We have built a good foundation on which new products and further acquisitions can be added. We are eagerly anticipating the shipment of new products later this fiscal year that will help us grow our revenue base and set the stage for significant growth during 2006," said CEO Howard Birndorf in a statement.


Research and development costs increased to $5.2 million from $4 million during last year's second quarter.


The company reported a net loss of $9.7 million, or $.20 per share, for the quarter, down from $12.9 million, or $.39 per share, for the same period in 2004.


As of June 30, Nanogen had $18.8 million in cash and cash equivalents and $13.1 million in short-term investments.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.